Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 9, Pages 2241
Publisher
MDPI AG
Online
2019-05-09
DOI
10.3390/ijms20092241
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
- (2018) G. R. Vanaja et al. Cell Communication and Signaling
- Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation
- (2018) Asadollah Mohammadi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
- (2018) Gilda Varricchi et al. CURRENT MEDICINAL CHEMISTRY
- The side effects of platinum-based chemotherapy drugs: a review for chemists
- (2018) Rabbab Oun et al. DALTON TRANSACTIONS
- A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
- (2018) Tingting Wang et al. Nature Communications
- Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
- (2018) Amit Singh et al. Nutrients
- Programming and Regulation of Metabolic Homeostasis by HDAC11
- (2018) Lei Sun et al. EBioMedicine
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
- (2018) Alan P. Kozikowski et al. ACS Chemical Neuroscience
- Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
- (2018) Ajimu Keremu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Entinostat for the treatment of breast cancer
- (2017) Dario Trapani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells
- (2017) Himavanth R. Gatla et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
- (2017) Yuankai Shi et al. Journal of Hematology & Oncology
- Wnt/beta-catenin pathway: modulating anticancer immune response
- (2017) Sachin Gopalkrishna Pai et al. Journal of Hematology & Oncology
- Differentiation stage-specific effect of histone deacetylase inhibitors on the expression of RORγT in human lymphocytes
- (2017) Anna Sałkowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Correction for Yang et al., “Cross Talk between Histone Deacetylase 4 and STAT6 in the Transcriptional Regulation of Arginase 1 during Mouse Dendritic Cell Differentiation”
- (2017) Quan Yang et al. MOLECULAR AND CELLULAR BIOLOGY
- Epigenetics and immunotherapy: The current state of play
- (2017) Jennifer Dunn et al. MOLECULAR IMMUNOLOGY
- Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma
- (2017) Li R. Kong et al. Molecular Oncology
- A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma
- (2017) Soham D. Puvvada et al. ONCOLOGY
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness
- (2017) Janina Leyk et al. Cell Death & Disease
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells
- (2017) Yin Li et al. Clinical Epigenetics
- The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
- (2017) Shuang-shuang Yang et al. Translational Neurodegeneration
- Apicidin, the Histone Deacetylase Inhibitor, Suppresses TH1 Polarization of Murine Bone Marrow-Derived Dendritic Cells
- (2017) I.D. Jung et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells
- (2017) Yukina Kawada et al. PLoS One
- The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
- (2017) Lulu Ni et al. Scientific Reports
- Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function
- (2017) Jianbing Huang et al. Scientific Reports
- Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma
- (2016) Li-Si Zeng et al. Aging-US
- Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes
- (2016) Chiara Angiolilli et al. ANNALS OF THE RHEUMATIC DISEASES
- Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro
- (2016) Hai-Fang Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Essential role of HDAC6 in the regulation of PD-L1 in melanoma
- (2016) M. Lienlaf et al. Molecular Oncology
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function
- (2016) Matthew Pace et al. PLoS Pathogens
- HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
- (2016) Elizabeth E. Hull et al. Biomed Research International
- Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
- (2016) Peter Campbell et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition
- (2015) Z Meng et al. ONCOGENE
- HDAC8: a multifaceted target for therapeutic interventions
- (2015) Alokta Chakrabarti et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements
- (2015) Michal Mielcarek et al. Frontiers in Cellular Neuroscience
- Manipulation of B-cell responses with histone deacetylase inhibitors
- (2015) Michaela Waibel et al. Nature Communications
- Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
- (2015) Han-Li Huang et al. Oncotarget
- Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1
- (2015) Qingsi Wu et al. Scientific Reports
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma
- (2015) Xiaosong Wu et al. NEOPLASIA
- Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo
- (2014) Nicole L. Regna et al. CLINICAL IMMUNOLOGY
- Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance
- (2014) Frank J. Kaiser et al. HUMAN MOLECULAR GENETICS
- Histone Deacetylase Inhibitors Modulate Interleukin 6-dependent CD4+T Cell Polarizationin Vitroandin Vivo
- (2014) Rainer Glauben et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- T-Bet Dependent Removal of Sin3A-Histone Deacetylase Complexes at the Ifng Locus Drives Th1 Differentiation
- (2014) S. Chang et al. JOURNAL OF IMMUNOLOGY
- A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs
- (2014) Fengdong Cheng et al. JOURNAL OF IMMUNOLOGY
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression
- (2014) Zhen-Hua Kang et al. PLoS One
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review
- (2013) Yoshimasa Saito et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
- (2013) Kelly A. Cycon et al. IMMUNOLOGY
- Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi-1 leukemia cells
- (2013) ZHI-HUA ZHANG et al. Molecular Medicine Reports
- The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma
- (2013) A Newbold et al. ONCOGENE
- The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
- (2013) Shiguo Zhu et al. PHARMACEUTICAL RESEARCH
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration
- (2013) Michal Mielcarek et al. PLOS BIOLOGY
- Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni
- (2013) Martin Marek et al. PLoS Pathogens
- Systemic cancer therapy: achievements and challenges that lie ahead
- (2013) Michael O. Palumbo et al. Frontiers in Pharmacology
- Histone/protein deacetylases and T-cell immune responses
- (2012) T. Akimova et al. BLOOD
- Impact of HDAC inhibitors on dendritic cell functions
- (2012) Jihane Frikeche et al. EXPERIMENTAL HEMATOLOGY
- HDAC11 is a novel drug target in carcinomas
- (2012) Hedwig E. Deubzer et al. INTERNATIONAL JOURNAL OF CANCER
- Trials with ‘epigenetic’ drugs: An update
- (2012) Angela Nebbioso et al. Molecular Oncology
- The determination and interpretation of the therapeutic index in drug development
- (2012) Patrick Y. Muller et al. NATURE REVIEWS DRUG DISCOVERY
- Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases: Figure 1
- (2011) Alexander J.P. Edwards et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- HDAC inhibitors block innate immunity
- (2011) K. A. Bode et al. BLOOD
- Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
- (2011) Yanis Boumber et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer
- (2011) Karrune V Woan et al. IMMUNOLOGY AND CELL BIOLOGY
- HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia
- (2011) Hao Geng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- Unknown
- (2011) Rainer Glauben et al. MOLECULAR MEDICINE
- Unknown
- (2011) Sung Choi et al. MOLECULAR MEDICINE
- Unknown
- (2011) Antonio Furlan et al. MOLECULAR MEDICINE
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit
- (2010) T.-Y. Lin et al. BLOOD
- Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils
- (2010) Hannu Kankaanranta et al. Journal of Inflammation-London
- Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS
- (2010) Maria A. Halili et al. JOURNAL OF LEUKOCYTE BIOLOGY
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
- (2010) W Song et al. LEUKEMIA
- Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality
- (2009) L. K. Jasperson et al. BLOOD
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
- (2009) D. D. Vo et al. CANCER RESEARCH
- Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors
- (2009) Julie L. Lucas et al. CELLULAR IMMUNOLOGY
- Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- (2009) P. Munster et al. CLINICAL CANCER RESEARCH
- CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin
- (2009) Sara A Wickström et al. EMBO JOURNAL
- Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-3
- (2009) Yaping Sun et al. JOURNAL OF IMMUNOLOGY
- Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
- (2008) Barbara Seliger CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
- (2008) Y.-S. Lee et al. CANCER RESEARCH
- Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
- (2008) A. F. Setiadi et al. CANCER RESEARCH
- Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice
- (2008) Pavan Reddy et al. JOURNAL OF CLINICAL INVESTIGATION
- A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
- (2008) S Balasubramanian et al. LEUKEMIA
- HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
- (2008) Andrew J. Wilson et al. MOLECULAR BIOLOGY OF THE CELL
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
- (2008) Alejandro Villagra et al. NATURE IMMUNOLOGY
- DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes
- (2008) Elizabeth A. Griffiths et al. SEMINARS IN HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started